Story perspectives

China Leads Drug Development as Trump Signs Biosecure Act

6/23/2026

Summary

China Leads

Poll of 117 leaders says China leads development and supply chain, while the U.S. leads quality, capital, commercialization and talent.
U.S. drug development share fell to 37% in 2024 from 48% in 2015, while China’s rose to 32% from 8%.
China recorded 5,215 trials in 2025, about double 2020.
The U.S. launched a program and the Biosecure Act signed by President Donald Trump to restrict dealings with non-U.S. biotech firms.

Summary

Innovent-Pfizer Deal

Innovent Biologics and Pfizer signed a $10.5 billion oncology deal covering co-development and co-commercialization of 12 programs with profit-sharing in the U.S. and Europe.
CFO You Fei said profit-sharing now includes Europe, while the U.S. holds over 80 percent of global pharma sales.
Morgan Stanley forecasts Chinese-origin drugs could make up 35 percent of new FDA approvals by 2040.
Song Ruilin urged policymakers to handle cross-border biotech deals prudently, respecting scientific and market principles.

1 of 2

China Leads

Poll of 117 leaders says China leads development and supply chain, while the U.S. leads quality, capital, commercialization and talent.
U.S. drug development share fell to 37% in 2024 from 48% in 2015, while China’s rose to 32% from 8%.
China recorded 5,215 trials in 2025, about double 2020.
The U.S. launched a program and the Biosecure Act signed by President Donald Trump to restrict dealings with non-U.S. biotech firms.

1 / 2